Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: Results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 7, 2014, Pages 913-925

  Nakamura, Yu ^a   Kitamura, Shin ^b   Homma, Akira ^c   Shiosakai, Kazuhito ^d   Matsui, Daiju ^d  

^a KAGAWA UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^c Tokyo Dementia Care Research and Training Center   (Japan)

^d DAIICHI SANKYO CO   (Japan)

Author keywords

Alzheimer's disease; Behavior; Cognition; Language; Memantine; Outpatients

Indexed keywords

MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; COGNITION; CONSTIPATION; CONTUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INSOMNIA; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; DOUBLE-BLIND METHOD; EUROPE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; JAPAN; MALE; MEMANTINE; PLACEBO EFFECT; RECEPTORS, N-METHYL-D-ASPARTATE; SPEECH;

EID: 84899415447     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.902446     Document Type: Article

References (29)

1. Reisberg B, Doody R, Stöffler A, et al. for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
2. Tariot PN, Farlow MR, Grossberg GT, et al. for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24
3. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24:20-7
4. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723
5. Kitamura S, Homma A, Nakamura Y, et al. Phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease-Efficacy, safety and recommended dose. Jpn J Geriatr Psychiat 2011;22:453-63
6. Niina R, Homma A, Sugai Y, et al. Reliability, validity and clinical availability of a Japanese version of severe impairment battery (SIB) and a Japanese version of modified Alzheimer's disease cooperative study-activities of daily living inventory (ADCS-ADL). Jpn J Geriatr Psychiat 2005;16:683-91
7. Homma A, Asada T, Arai H, et al. Clinical global assessment for dementia patients. Clinician's interview-based impression of change plus-Japan (CIBIC plus-J) concept and assessment manual. Jpn J Geriatr Psychiat 1997;8:855-69
8. Nakamura Y, Homma A, Kitamura S, et al. Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease-Efficacy and safety. Jpn J Geriatr Psychiat 2011;22:464-73
9. Ferris S, Ihl R, Robert P, et al. Treatment effects of memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement 2009;5:369-74
10. Ferris S, Ihl R, Robert P, et al. Severe impairment battery language scale: a Language Assessment tool for Alzheimer's disease patients. Alzheimers Dement 2009;5:375-9
11. Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20:459-64
12. Asada T, Homma A, Kimura M, et al. Study on the reliability of the Japanese version of the BEHAVE-AD. Jpn J Geriatr Psychiat 1999;10:825-34
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington, DC; 1994
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease; report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-98
16. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-9
17. Homma A, Asada T, Arai H, et al. Clinical assessment for patients with age-associated dementia. Global and psychometric assessment. Jpn J Geriatr Psychiat 1999;10:193-229
18. Panisset M, Roudier M, Saxton J, et al. Severe impairment battery; a neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-5
19. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment, battery; concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S51-6
20. Homma A, Niina R, Ishii T, et al. Development of a new rating scale for dementia in the elderly: mental function impairment scale (MENFIS). Jpn J Geriatr Psychiat 1991;10:1217-22
21. Statistical principles for clinical trials (The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH] E9). ICH, Geneva, Switzerland. Available from: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/ statistical-principles-for-clinical-trials.html [Last accessed 10 December 2013]
22. Schmitt F, van Dyck C, Wichems C, et al. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord 2006;20:255-62
23. Tocco M, Bayles K, Lopez OL, et al. Effects of memantine treatment on language abilities and functional communication: a review of data. Aphasiology 2014;28:236-57
24. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341-8
25. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-45
26. Survey of Institutions and Establishments for Long-term Care 2010: summary of Results. Ministry of Health, Labour and Welfare, Tokyo, Japan. Available from: http://www.mhlw.go.jp/english/index. html [Last accessed 10 December 2013]
27. Nakamura Y. Investigation of the effects of use of nursing care services on changes of status of nursing care for patients with dementia and consideration of the effect on CIBIC-plus by these changes. Jpn J Geriatr Psychiat 2010;21:685-94
28. Nakamura Y, Kitamura S, Homma A, et al. Tolerability and efficacy of the long-term administration of memantine hydrochloride (Memary) in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat 2014; In press
29. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-8